Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.concorddrugs.in | |
Market Cap | 24.66 Cr. | |
Enterprise Value(EV) | 35.48 Cr. | 2021-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 2.17 | Trailing Twelve Months Ending 2021-12 |
Price-Earning Ratio (PE) | 12.98 | Trailing Twelve Months Ending 2021-12 |
Industry PE | 28.96 | Trailing Twelve Months Ending 2021-12 |
Book Value / Share | 32.40 | Trailing Twelve Months Ending 2021-12 |
Price to Book Value | 0.87 | Calculated using Price: 28.20 |
Dividend Yield | 0.00 | Period Ending 2021-03 |
No. of Shares Subscribed | 0.87 Cr. | 8,743,750 Shares |
FaceValue | 10 | |
Company Profile | ||
Concord Drugs is a public limited company established in the year 1995. The company is one among selected few pharmaceutical companies in India with dedicated state of art WHO-GMP certified facility. The company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide its customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing. The company has manufacturing license issued by the Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad. Concord Drugs operates a state of the art, cGMP contract manufacturing Formulation-Fill-Finish facility, providing comprehensive pharmaceutical development and manufacturing services for drug products. Concord Drugs Limited has two manufacturing facilities built to comply with standards stipulated by Regulatory bodies. Business area of the company: Concord Drugs is engaged in developing new products Viz MUPS (Multiple Unit Pellet System), Sustained Release, Modified Release pellets with Innovative Drug Delivery Technologies by utilizing best and latest processing machinery. Products Concord Drugs offers products of international standards through innovations with foresight of its responsibility towards the Society at large:
|
1 Day |
|
+0.36% |
1 Week |
|
+0.36% |
1 Month |
|
-8.14% |
3 Month |
|
-10.19% |
6 Month |
|
-7.84% |
1 Year |
|
-16.69% |
2 Year |
|
+73.54% |
5 Year |
|
-45.98% |
10 Year |
|
9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | 8.85 | 2.72 | 5.37 | 12.32 | 0.94 | 1.69 | 1.92 | 1.41 | 13.06 | |
Return on Capital Employed (%) | 6.30 | 7.15 | 11.33 | 15.90 | 8.84 | 7.49 | 6.17 | 6.06 | 15.69 | |
Return on Assets (%) | 2.93 | 0.79 | 1.41 | 3.28 | 0.30 | 0.40 | 0.43 | 0.47 | 6.08 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
Shh. Funds | 14 | 15 | 13 | 15 | 19 | 19 | 23 | 23 | 27 | 28 | |
Non Curr. Liab. | 12 | 12 | 13 | 17 | 7 | 6 | 4 | 7 | 7 | 6 | |
Curr. Liab. | 15 | 18 | 28 | 21 | 29 | 81 | 56 | 27 | 16 | 18 | |
Minority Int. | |||||||||||
Equity & Liab. | 41 | 45 | 54 | 52 | 56 | 106 | 83 | 58 | 50 | 52 | |
Non Curr. Assets | 20 | 21 | 19 | 16 | 25 | 14 | 13 | 12 | 14 | 14 | |
Curr. Assets | 21 | 23 | 36 | 37 | 30 | 92 | 70 | 46 | 36 | 38 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 41 | 45 | 54 | 52 | 56 | 106 | 83 | 58 | 50 | 52 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
Net Sales | 28 | 34 | 40 | 51 | 57 | 52 | 48 | 51 | 51 | 52 | |
Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Total Income | 28 | 34 | 40 | 51 | 58 | 52 | 48 | 51 | 51 | 52 | |
Total Expenditure | -26 | -31 | -33 | -42 | -52 | -47 | -44 | -48 | -48 | -46 | |
PBIDT | 2 | 3 | 7 | 8 | 6 | 5 | 4 | 3 | 3 | 6 | |
Interest | -1 | -2 | -3 | -3 | -2 | -2 | -2 | -2 | -1 | -2 | |
Depreciation | -1 | -1 | -4 | -3 | -3 | -2 | -2 | -1 | -1 | -2 | |
Taxation | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | -1 | -1 | |
Exceptional Items | 4 | 0 | |||||||||
PAT | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 3 | 2 | |
Adjusted EPS | 1 | 0 | 1 | 2 | 0 | 0 | 1 | 0 | 4 | 2 |
Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | -3 | 1 | 2 | 2 | 4 | 2 | 7 | 1 | 2 | 2 | |
Cash Fr. Inv. | -2 | -10 | -2 | -1 | 0 | -1 | -2 | 0 | -1 | -4 | |
Cash Fr. Finan. | 6 | 8 | 0 | -1 | -4 | -4 | -5 | -1 | -2 | 2 | |
Net Change | 0 | -1 | 0 | 0 | 0 | -3 | 0 | 0 | 0 | 0 | |
Cash & Cash Eqvt | 1 | 0 | 0 | 0 | 0 | -3 | 0 | 0 | 0 | 0 |
Tue, 17 May 2022
Board Meeting Intimation for Audited Financial Results For The Quarter And Year Ended 31.03.2022 Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve Audited financial results for the quarter and year ended 31.03.2022 |
Fri, 06 May 2022
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer Resignation of CS |
Fri, 06 May 2022
Board Meeting Outcome for Resignation Of CS Resignation of CS |
Wed, 18 May 2022 |
|
|
|
|
|